CureVac AG

CureVac uses mRNA as an information carrier, which enables the body to produce its own active ingredients for the fight against various diseases.

CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered into a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 900 people across its sites in Tübingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.

Category Biotechnology
Working areas Biotechnology, Research, Medical products, Production
Year of foundation
2000
Employees
900

News

24.06.2025

CureVac Announces Voting Results of General Meeting

CureVac N.V. (Nasdaq: CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the…

12.06.2025

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in…

15.05.2025

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

TÜBINGEN, Germany/BOSTON, USA –  May 15, 2025CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biotech company developing a new class of transformative medicines based on…

28.03.2025

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today…